WO2004083234A3 - Insulin polypeptide-oligomer conjugates, proinsulin polypeptide-oligomer conjugates and methods of synthesizing same - Google Patents

Insulin polypeptide-oligomer conjugates, proinsulin polypeptide-oligomer conjugates and methods of synthesizing same Download PDF

Info

Publication number
WO2004083234A3
WO2004083234A3 PCT/US2004/007310 US2004007310W WO2004083234A3 WO 2004083234 A3 WO2004083234 A3 WO 2004083234A3 US 2004007310 W US2004007310 W US 2004007310W WO 2004083234 A3 WO2004083234 A3 WO 2004083234A3
Authority
WO
WIPO (PCT)
Prior art keywords
polypeptide
proinsulin
oligomer
oligomer conjugates
methods
Prior art date
Application number
PCT/US2004/007310
Other languages
French (fr)
Other versions
WO2004083234A2 (en
Inventor
Nnochiri N Ekwuribe
Balasingam Radhakrishnan
Richard Soltero
Monica Puskas
Diti Sangal
Original Assignee
Nobex Corp
Nnochiri N Ekwuribe
Balasingam Radhakrishnan
Richard Soltero
Monica Puskas
Diti Sangal
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nobex Corp, Nnochiri N Ekwuribe, Balasingam Radhakrishnan, Richard Soltero, Monica Puskas, Diti Sangal filed Critical Nobex Corp
Priority to ES04719724.9T priority Critical patent/ES2612937T3/en
Priority to DK04719724.9T priority patent/DK1613343T3/en
Priority to EP04719724.9A priority patent/EP1613343B1/en
Priority to JP2006507037A priority patent/JP4602968B2/en
Publication of WO2004083234A2 publication Critical patent/WO2004083234A2/en
Publication of WO2004083234A3 publication Critical patent/WO2004083234A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

Methods for synthesizing proinsulin polypeptides are described that include contacting a proinsulin polypeptide including an insulin polypeptide coupled to one or more peptides by peptide bond(s) capable of being cleaved to yield the insulin polypeptide with an oligomer under conditions sufficient to couple the oligomer to the insulin polypeptide portion of the proinsulin polypeptide and provide a proinsulin polypeptide-oligomer conjugate, and cleaving the one or more peptides from the proinsulin polypeptide-oligomer conjugate to provide the insulin polypeptide-oligomer conjugate. Methods of synthesizing proinsulin polypeptide-oligomer conjugates are also provided as are proinsulin polypeptide-oligomer conjugates. Methods of synthesizing C-peptide polypeptide-oligomer conjugates and other pro-polypeptide-oligomer conjugates are also provided.
PCT/US2004/007310 2003-03-14 2004-03-11 Insulin polypeptide-oligomer conjugates, proinsulin polypeptide-oligomer conjugates and methods of synthesizing same WO2004083234A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
ES04719724.9T ES2612937T3 (en) 2003-03-14 2004-03-11 Insulin and oligomer polypeptide conjugates, proinsulin and oligomer polypeptide conjugates and methods for their synthesis
DK04719724.9T DK1613343T3 (en) 2003-03-14 2004-03-11 INSULIN-POLYPEPTIDE-OLIGOMER CONJUGATES, PROINSULIN-POLYPEPTIDE-OLIGOMER CONJUGATES, AND METHODS FOR SYNTHESIS
EP04719724.9A EP1613343B1 (en) 2003-03-14 2004-03-11 Insulin polypeptide-oligomer conjugates, proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
JP2006507037A JP4602968B2 (en) 2003-03-14 2004-03-11 Insulin polypeptide-oligomer conjugates, proinsulin polypeptide-oligomer conjugates and methods for their synthesis

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/389,499 2003-03-14
US10/389,499 US7312192B2 (en) 2001-09-07 2003-03-14 Insulin polypeptide-oligomer conjugates, proinsulin polypeptide-oligomer conjugates and methods of synthesizing same

Publications (2)

Publication Number Publication Date
WO2004083234A2 WO2004083234A2 (en) 2004-09-30
WO2004083234A3 true WO2004083234A3 (en) 2005-08-04

Family

ID=33029662

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/007310 WO2004083234A2 (en) 2003-03-14 2004-03-11 Insulin polypeptide-oligomer conjugates, proinsulin polypeptide-oligomer conjugates and methods of synthesizing same

Country Status (8)

Country Link
US (1) US7312192B2 (en)
EP (1) EP1613343B1 (en)
JP (1) JP4602968B2 (en)
DK (1) DK1613343T3 (en)
ES (1) ES2612937T3 (en)
PL (1) PL1613343T3 (en)
PT (1) PT1613343T (en)
WO (1) WO2004083234A2 (en)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6913903B2 (en) * 2001-09-07 2005-07-05 Nobex Corporation Methods of synthesizing insulin polypeptide-oligomer conjugates, and proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
US7166571B2 (en) * 2001-09-07 2007-01-23 Biocon Limited Insulin polypeptide-oligomer conjugates, proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
US7312192B2 (en) * 2001-09-07 2007-12-25 Biocon Limited Insulin polypeptide-oligomer conjugates, proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
CA2504287A1 (en) * 2002-11-26 2004-06-10 Nobex Corporation Natriuretic compounds, conjugates, and uses thereof
CA2526957C (en) * 2003-07-25 2011-07-12 Conjuchem Inc. Long lasting insulin derivatives and methods thereof
US7318925B2 (en) 2003-08-08 2008-01-15 Amgen Fremont, Inc. Methods of use for antibodies against parathyroid hormone
ES2321088T3 (en) 2003-08-08 2009-06-02 Amgen Fremont Inc. ANTIBODIES DIRECTED AGAINST THE PARTIROID HORMONE (PTH) AND USES OF THE SAME.
WO2006076471A2 (en) * 2005-01-12 2006-07-20 Nobex Corporation Bnp conjugates and methods of use
EP1843790A2 (en) * 2005-01-27 2007-10-17 Novo Nordisk A/S Insulin derivatives conjugated with structurally well defined branched polymers
WO2006087354A2 (en) * 2005-02-16 2006-08-24 Novo Nordisk A/S Insulinotropic agents conjugated with structurally well defined branched polymers
EP1934252B1 (en) 2005-10-13 2015-06-24 Biocon Limited Process for the preparation of insulin conjugates.
ES2331342B1 (en) * 2006-05-22 2010-10-13 Consejo Superior Investg.Cientificas USE OF PROINSULIN FOR THE PREPARATION OF A NEUROPROTECTING PHARMACEUTICAL COMPOSITION, THERAPEUTIC COMPOSITION CONTAINING IT AND ITS APPLICATIONS.
RU2007131782A (en) * 2007-08-22 2009-02-27 Общество с ограниченной ответственностью "Концерн O3" (RU) HYPOGLYCEMIC PRODUCT AND METHOD FOR PRODUCING IT
RU2007137048A (en) * 2007-10-05 2009-04-10 Общество С Ограниченной Ответственностью "Концерн О3" (Ru) MEDICINE FOR TREATMENT AND PREVENTION OF COMPLICATIONS IN SUGAR DIABETES
PL2910570T3 (en) 2008-03-18 2017-06-30 Novo Nordisk A/S Protease stabilized, acylated insulin analogues
RU2409669C9 (en) * 2008-08-18 2012-05-27 ООО "Саентифик Фьючер Менеджмент" ("Scientific Future Management", "SFM") Method for immobilising biologically active substance (bas) on carrier (versions) and bas-carrier conjugate produced by such methods
WO2010033204A2 (en) * 2008-09-19 2010-03-25 Nektar Therapeutics Polymer conjugates of c-peptides
US20110166063A1 (en) 2008-09-19 2011-07-07 Nektar Therapeutics Polymer conjugates of therapeutic peptides
RU2395296C1 (en) * 2009-02-19 2010-07-27 Общество С Ограниченной Ответственностью "Концерн О3" Method for making oral proinsulin preparation
EP2504019A2 (en) 2009-11-25 2012-10-03 ArisGen SA Mucosal delivery composition comprising a peptide complexed with a crown compound and/or a counter ion
EP2571896A4 (en) 2010-05-17 2014-01-08 Cebix Inc Pegylated c-peptide
CN102675452B (en) * 2011-03-17 2015-09-16 重庆富进生物医药有限公司 Tool continues the conjugate of insulin human that is hypoglycemic and that combined by height and analogue
KR20130049671A (en) * 2011-11-04 2013-05-14 한미사이언스 주식회사 Method for preparation of biological active polypeptide conjugate
AR090281A1 (en) 2012-03-08 2014-10-29 Hanmi Science Co Ltd IMPROVED PROCESS FOR THE PREPARATION OF A PHYSIOLOGICALLY ACTIVE POLYPEPTIDE COMPLEX
CN110087674B (en) 2016-12-16 2023-01-03 诺和诺德股份有限公司 Pharmaceutical composition containing insulin

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5646242A (en) * 1994-11-17 1997-07-08 Eli Lilly And Company Selective acylation of epsilon-amino groups

Family Cites Families (122)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3256153A (en) * 1963-02-08 1966-06-14 Smith Kline French Lab Method of stabilizing wax-fat coating materials and product thereof
US4003792A (en) * 1967-07-01 1977-01-18 Miles Laboratories, Inc. Conjugates of acid polysaccharides and complex organic substances
US3950517A (en) * 1970-05-08 1976-04-13 National Research Development Corporation Insulin derivatives
GB1381274A (en) * 1971-01-28 1975-01-22 Nat Res Dev Insulin derivatives
US3919411A (en) 1972-01-31 1975-11-11 Bayvet Corp Injectable adjuvant and compositions including such adjuvant
US4044196A (en) * 1972-03-30 1977-08-23 Bayer Aktiengesellschaft Crosslinked copolymers of α,β-olefinically unsaturated dicarboxylic anhydrides
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
FR2408387A2 (en) * 1975-06-30 1979-06-08 Oreal COMPOSITIONS BASED ON AQUEOUS DISPERSIONS OF LIPID SPHERULES
US4087390A (en) * 1977-02-02 1978-05-02 Eli Lilly And Company Somatostatin analogs and intermediates thereto
US4093574A (en) * 1977-02-02 1978-06-06 Eli Lilly And Company Somatostatin analogs and intermediates thereto
JPS53116315A (en) 1977-03-17 1978-10-11 Ueno Seiyaku Oyo Kenkyujo Kk Powder or granular containing improved sorbinic acid
US4100117A (en) * 1977-04-21 1978-07-11 Eli Lilly And Company Somatostatin analogs and intermediates thereto
US4253998A (en) * 1979-03-09 1981-03-03 American Home Products Corporation Peptides related to somatostatin
JPS54148722A (en) * 1978-05-12 1979-11-21 Takeda Chem Ind Ltd Nonapeptide and its preparation
US4277394A (en) * 1979-04-23 1981-07-07 Takeda Chemical Industries, Ltd Tetrapeptidehydrazide derivatives
GB2051574B (en) * 1979-05-10 1984-01-18 Kyoto Pharma Ind Adjuvant for promoting absorption of pharmacologically active substances through the rectum
US4469681A (en) * 1979-07-31 1984-09-04 The Rockefeller University Method and system for the controlled release of biologically active substances to a body fluid
US4348387A (en) * 1979-07-31 1982-09-07 The Rockefeller University Method and system for the controlled release of biologically active substances to a body fluid
FR2465486A1 (en) * 1979-09-21 1981-03-27 Roussel Uclaf NEW APPLICATION USING LH-RH OR AGONISTS
US4554101A (en) 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
US4698264A (en) 1982-08-02 1987-10-06 Durkee Industrial Foods, Corp. Particulate composition and process for making same
IL68769A (en) * 1983-05-23 1986-02-28 Hadassah Med Org Pharmaceutical compositions containing insulin for oral administration
US4585754A (en) * 1984-01-09 1986-04-29 Valcor Scientific, Ltd. Stabilization of proteins and peptides by chemical binding with chondroitin
US4717566A (en) * 1984-03-19 1988-01-05 Alza Corporation Dosage system and method of using same
US4684524A (en) * 1984-03-19 1987-08-04 Alza Corporation Rate controlled dispenser for administering beneficial agent
US4849405A (en) * 1984-05-09 1989-07-18 Synthetic Blood Corporation Oral insulin and a method of making the same
US4963367A (en) 1984-04-27 1990-10-16 Medaphore, Inc. Drug delivery compositions and methods
US4839341A (en) * 1984-05-29 1989-06-13 Eli Lilly And Company Stabilized insulin formulations
US4622392A (en) 1984-06-21 1986-11-11 Health Research Inc. (Roswell Park Division) Thiophospholipid conjugates of antitumor agents
US4629621A (en) * 1984-07-23 1986-12-16 Zetachron, Inc. Erodible matrix for sustained release bioactive composition
US4797288A (en) * 1984-10-05 1989-01-10 Warner-Lambert Company Novel drug delivery system
US4946828A (en) * 1985-03-12 1990-08-07 Novo Nordisk A/S Novel insulin peptides
US5157021A (en) 1985-03-15 1992-10-20 Novo Nordisk A/S Insulin derivatives and pharmaceutical preparations containing these derivatives
DK129385A (en) * 1985-03-22 1986-09-23 Novo Industri As PEPTIDES AND PREPARATION THEREOF
US4917888A (en) * 1985-06-26 1990-04-17 Cetus Corporation Solubilization of immunotoxins for pharmaceutical compositions using polymer conjugation
SE457326B (en) * 1986-02-14 1988-12-19 Lejus Medical Ab PROCEDURES FOR PREPARING A QUICK SUBSTANTIAL CANDLES CONTAINING BLA MICROCRISTALLIN CELLULOSA
ZA877505B (en) 1986-10-14 1989-05-30 Lilly Co Eli Process for transforming a human insulin precursor to human insulin
GB8706313D0 (en) * 1987-03-17 1987-04-23 Health Lab Service Board Treatment & prevention of viral infections
US5093198A (en) * 1987-06-19 1992-03-03 Temple University Adjuvant-enhanced sustained release composition and method for making
DE3721721C1 (en) * 1987-07-01 1988-06-09 Hoechst Ag Process for coating granules
US5080891A (en) 1987-08-03 1992-01-14 Ddi Pharmaceuticals, Inc. Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols
JPH01308231A (en) 1988-06-03 1989-12-12 Takeda Chem Ind Ltd Stabilized pharmaceutical composition and production thereof
US5055300A (en) 1988-06-17 1991-10-08 Basic Bio Systems, Inc. Time release protein
DK336188D0 (en) * 1988-06-20 1988-06-20 Nordisk Gentofte propeptides
ATE101620T1 (en) * 1988-06-23 1994-03-15 Hoechst Ag MINI-PROINSULIN, ITS PREPARATION AND USE.
US5162430A (en) * 1988-11-21 1992-11-10 Collagen Corporation Collagen-polymer conjugates
US5306500A (en) * 1988-11-21 1994-04-26 Collagen Corporation Method of augmenting tissue with collagen-polymer conjugates
HUT56857A (en) 1988-12-23 1991-10-28 Novo Nordisk As Human insulin analogues
US4994439A (en) * 1989-01-19 1991-02-19 California Biotechnology Inc. Transmembrane formulations for drug administration
US5089261A (en) * 1989-01-23 1992-02-18 Cetus Corporation Preparation of a polymer/interleukin-2 conjugate
US5182258A (en) * 1989-03-20 1993-01-26 Orbon Corporation Systemic delivery of polypeptides through the eye
US5324844A (en) * 1989-04-19 1994-06-28 Enzon, Inc. Active carbonates of polyalkylene oxides for modification of polypeptides
US5286637A (en) * 1989-08-07 1994-02-15 Debiopharm, S.A. Biologically active drug polymer derivatives and method for preparing same
US5013556A (en) * 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5312808A (en) * 1989-11-22 1994-05-17 Enzon, Inc. Fractionation of polyalkylene oxide-conjugated hemoglobin solutions
US5650388A (en) * 1989-11-22 1997-07-22 Enzon, Inc. Fractionated polyalkylene oxide-conjugated hemoglobin solutions
US5545618A (en) * 1990-01-24 1996-08-13 Buckley; Douglas I. GLP-1 analogs useful for diabetes treatment
US5595732A (en) 1991-03-25 1997-01-21 Hoffmann-La Roche Inc. Polyethylene-protein conjugates
JPH06507172A (en) * 1991-04-19 1994-08-11 アフィニティー　バイオテック，インコーポレイテッド Convertible microemulsion formulation
US5304473A (en) * 1991-06-11 1994-04-19 Eli Lilly And Company A-C-B proinsulin, method of manufacturing and using same, and intermediates in insulin production
US5206219A (en) * 1991-11-25 1993-04-27 Applied Analytical Industries, Inc. Oral compositions of proteinaceous medicaments
US5693769A (en) 1991-12-13 1997-12-02 Transcell Technologies, Inc. Glycosylated steroid derivatives for transport across biological membranes and process for making and using same
GB9212511D0 (en) * 1992-06-12 1992-07-22 Cortecs Ltd Pharmaceutical compositions
US5262172A (en) * 1992-06-19 1993-11-16 Digestive Care Inc. Compositions of gastric acid-resistant microspheres containing buffered bile acids
US5415872A (en) * 1992-06-22 1995-05-16 Digestive Care Inc. Compositions of gastric acid-resistant microspheres containing salts of bile acids
JPH0635027A (en) * 1992-07-22 1994-02-10 Nikon Corp Automatic exposure device for camera and photometry device for camera
US6093391A (en) * 1992-10-08 2000-07-25 Supratek Pharma, Inc. Peptide copolymer compositions
GB9316895D0 (en) 1993-08-13 1993-09-29 Guy S And St Thomas Hospitals Hepatoselective insulin analogues
US5298643A (en) * 1992-12-22 1994-03-29 Enzon, Inc. Aryl imidate activated polyalkylene oxides
US5349001A (en) * 1993-01-19 1994-09-20 Enzon, Inc. Cyclic imide thione activated polyalkylene oxides
US5321095A (en) 1993-02-02 1994-06-14 Enzon, Inc. Azlactone activated polyalkylene oxides
US5298410A (en) * 1993-02-25 1994-03-29 Sterling Winthrop Inc. Lyophilized formulation of polyethylene oxide modified proteins with increased shelf-life
US5681811A (en) 1993-05-10 1997-10-28 Protein Delivery, Inc. Conjugation-stabilized therapeutic agent compositions, delivery and diagnostic formulations comprising same, and method of making and using the same
US6191105B1 (en) * 1993-05-10 2001-02-20 Protein Delivery, Inc. Hydrophilic and lipophilic balanced microemulsion formulations of free-form and/or conjugation-stabilized therapeutic agents such as insulin
US5359030A (en) * 1993-05-10 1994-10-25 Protein Delivery, Inc. Conjugation-stabilized polypeptide compositions, therapeutic delivery and diagnostic formulations comprising same, and method of making and using the same
US5830853A (en) 1994-06-23 1998-11-03 Astra Aktiebolag Systemic administration of a therapeutic preparation
TW402506B (en) * 1993-06-24 2000-08-21 Astra Ab Therapeutic preparation for inhalation
US5506203C1 (en) * 1993-06-24 2001-02-06 Astra Ab Systemic administration of a therapeutic preparation
IS1796B (en) * 1993-06-24 2001-12-31 Ab Astra Inhaled polypeptide formulation composition which also contains an enhancer compound
US5747445A (en) * 1993-06-24 1998-05-05 Astra Aktiebolag Therapeutic preparation for inhalation
PT792290E (en) * 1993-09-17 2002-01-30 Novo Nordisk As INSULINA ACILADA
US5919455A (en) * 1993-10-27 1999-07-06 Enzon, Inc. Non-antigenic branched polymer conjugates
US5605976A (en) 1995-05-15 1997-02-25 Enzon, Inc. Method of preparing polyalkylene oxide carboxylic acids
DE69434626D1 (en) * 1993-11-17 2006-04-20 Athena Neurosciences Inc TRANSPARENT LIQUID FOR THE ADMINISTRATION OF CAPTIVATED MEDICAMENTS
US5461031A (en) 1994-06-16 1995-10-24 Eli Lilly And Company Monomeric insulin analog formulations
US5504188A (en) * 1994-06-16 1996-04-02 Eli Lilly And Company Preparation of stable zinc insulin analog crystals
US5730990A (en) * 1994-06-24 1998-03-24 Enzon, Inc. Non-antigenic amine derived polymers and polymer conjugates
GB9417524D0 (en) 1994-08-31 1994-10-19 Cortecs Ltd Pharmaceutical compositions
US5738846A (en) * 1994-11-10 1998-04-14 Enzon, Inc. Interferon polymer conjugates and process for preparing the same
US5693609A (en) * 1994-11-17 1997-12-02 Eli Lilly And Company Acylated insulin analogs
CA2206852A1 (en) * 1994-12-07 1996-06-13 Novo Nordisk A/S Polypeptide with reduced allergenicity
DE95907193T1 (en) * 1994-12-29 2005-02-10 Savient Pharmaceuticals, Inc. PREPARATION OF HUMANINE SULIN
US5932462A (en) * 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
US5907030A (en) * 1995-01-25 1999-05-25 University Of Southern California Method and compositions for lipidization of hydrophilic molecules
US6251856B1 (en) * 1995-03-17 2001-06-26 Novo Nordisk A/S Insulin derivatives
AR002976A1 (en) * 1995-03-31 1998-05-27 Lilly Co Eli PARENTERAL PHARMACEUTICAL FORMULATIONS OF LONG-TERM EFFECT OF INSULIN; CRYSTALS OF SUCH ANALOGUES APPLICABLE IN SUCH FORMULATIONS AND PROCEDURE OF THE FORMULATIONS MENTIONED
US5606038A (en) * 1995-04-10 1997-02-25 Competitive Technologies, Inc. Amphiphilic polyene macrolide antibiotic compounds
ES2093593T1 (en) * 1995-05-05 1997-01-01 Hoffmann La Roche RECOMBINANT OBESE PROTEINS (OB).
US5824638A (en) 1995-05-22 1998-10-20 Shire Laboratories, Inc. Oral insulin delivery
US5631347A (en) * 1995-06-07 1997-05-20 Eli Lilly And Company Reducing gelation of a fatty acid-acylated protein
US5700904A (en) 1995-06-07 1997-12-23 Eli Lilly And Company Preparation of an acylated protein powder
GB9516268D0 (en) * 1995-08-08 1995-10-11 Danbiosyst Uk Compositiion for enhanced uptake of polar drugs from the colon
US5766620A (en) * 1995-10-23 1998-06-16 Theratech, Inc. Buccal delivery of glucagon-like insulinotropic peptides
US5866538A (en) * 1996-06-20 1999-02-02 Novo Nordisk A/S Insulin preparations containing NaCl
US5948751A (en) * 1996-06-20 1999-09-07 Novo Nordisk A/S X14-mannitol
GB9613858D0 (en) * 1996-07-02 1996-09-04 Cortecs Ltd Hydrophobic preparations
WO1998002460A1 (en) * 1996-07-11 1998-01-22 Novo Nordisk A/S Selective acylation method
US5905140A (en) * 1996-07-11 1999-05-18 Novo Nordisk A/S, Novo Alle Selective acylation method
US5874111A (en) * 1997-01-07 1999-02-23 Maitra; Amarnath Process for the preparation of highly monodispersed polymeric hydrophilic nanoparticles
US5830918A (en) 1997-01-15 1998-11-03 Terrapin Technologies, Inc. Nonpeptide insulin receptor agonists
US6043214A (en) * 1997-03-20 2000-03-28 Novo Nordisk A/S Method for producing powder formulation comprising an insulin
US5898028A (en) * 1997-03-20 1999-04-27 Novo Nordisk A/S Method for producing powder formulation comprising an insulin
PE79099A1 (en) * 1997-06-13 1999-08-24 Lilly Co Eli STABLE INSULIN FORMULATIONS
EA200000453A1 (en) * 1997-10-24 2000-10-30 Эли Лилли Энд Компани COMPOSITIONS OF INSOLUBLE INSULIN
ZA989744B (en) * 1997-10-31 2000-04-26 Lilly Co Eli Method for administering acylated insulin.
US6211144B1 (en) * 1998-10-16 2001-04-03 Novo Nordisk A/S Stable concentrated insulin preparations for pulmonary delivery
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
JP3406244B2 (en) * 1999-04-30 2003-05-12 伊藤ハム株式会社 Method for producing recombinant insulin from novel fusion protein
US7060675B2 (en) * 2001-02-15 2006-06-13 Nobex Corporation Methods of treating diabetes mellitus
US6828297B2 (en) * 2001-06-04 2004-12-07 Nobex Corporation Mixtures of insulin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US7312192B2 (en) * 2001-09-07 2007-12-25 Biocon Limited Insulin polypeptide-oligomer conjugates, proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
DK1430082T3 (en) * 2001-09-07 2010-01-18 Biocon Ltd Process for the Synthesis of Insulin Polypeptide Oligomer Conjugates and Proinsulin Polypeptide Oligomer Conjugates and Method for Synthesis thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5646242A (en) * 1994-11-17 1997-07-08 Eli Lilly And Company Selective acylation of epsilon-amino groups

Also Published As

Publication number Publication date
US7312192B2 (en) 2007-12-25
EP1613343A2 (en) 2006-01-11
DK1613343T3 (en) 2017-02-06
JP2006520384A (en) 2006-09-07
WO2004083234A2 (en) 2004-09-30
US20030228652A1 (en) 2003-12-11
EP1613343A4 (en) 2008-03-05
ES2612937T3 (en) 2017-05-19
JP4602968B2 (en) 2010-12-22
PT1613343T (en) 2017-02-10
PL1613343T3 (en) 2017-05-31
EP1613343B1 (en) 2016-12-07

Similar Documents

Publication Publication Date Title
WO2004083234A3 (en) Insulin polypeptide-oligomer conjugates, proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
WO2003022996A3 (en) Methods of synthesizing insulin polypeptide-oligomer conjugates, and proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
WO2001005950A3 (en) Methods for displaying (poly)peptides/proteins on bacteriophage particles via disulfide bonds
WO2006083301A3 (en) Immunogenic compositions comprising hmgb1 polypeptides
WO2004058946A3 (en) Protein arrays
PT2241575E (en) Igf-1 fusion polypeptides and therapeutic uses thereof
WO2005055950A3 (en) Glycopegylated factor ix
WO2006031811A3 (en) Glycopegylated interferon alpha
WO2005051327A3 (en) Glycopegylated erythropoietin
MX2009002999A (en) Protease resistant insulin analogues.
IL182716A0 (en) Method for purifying fsh
AU2002360331A1 (en) Egviii endoglucanase and nucleic acids encoding the same
AU2002217010A1 (en) Peptides, the production and use thereof for binding immunoglobulins
AU2650597A (en) Novel fas antigen derivatives
WO2001047956A3 (en) Method for obtaining proteins having improved functional characteristics
WO2002012899A3 (en) Peptides presented by cells
WO2004025264A3 (en) Rapidly degraded reporter fusion proteins
MXPA00009564A (en) Chimeric protein containing an intramolecular chaperone-like sequence and its application to insulin production.
WO2003089451A3 (en) Antibodies specific for mucin polypeptide
WO2003099848A3 (en) Method for universal enzymatic production of bioactive peptides
WO2000058465A3 (en) Flint polypeptide analogs
WO2000068416A3 (en) Method for localising proteases which split substrates that are specifically connected by a membrane
WO2003099847A3 (en) Method for enzymatic production of glp-1 (7-36) amide peptides
WO2005067368A3 (en) Production of glucagon like peptide 2 and analogs
WO2004063214A3 (en) Antibodies that specifically recognize sumo-conjugated proteins

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2215/CHENP/2005

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2006507037

Country of ref document: JP

REEP Request for entry into the european phase

Ref document number: 2004719724

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2004719724

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2004719724

Country of ref document: EP

DPEN Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101)